Perspective Therapeutics (CATX) Non-Current Assets (2011 - 2026)
Perspective Therapeutics (CATX) posted Non-Current Assets of $135.4 million for Q1 2026, up 14.2% sequentially from $118.6 million in Q4 2025, and up 19.2% YoY from $113.6 million in Q1 2025.
Perspective Therapeutics (CATX) Non-Current Assets (2011 - 2026) Analysis & Trends
Perspective Therapeutics has reported Non-Current Assets for 16 years, with the latest figure at $135.4 million in Q1 2026.
- Quarterly Non-Current Assets rose 19.2% year-over-year to $135.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $485.1 million (up 11.21% YoY) and the FY2025 annual result came in at $118.6 million, up 7.86% from the prior year.
- Non-Current Assets improved to $135.4 million in Q1 2026 per CATX's latest filing, from $118.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $135.4 million in Q1 2026 and troughed at $3.4 million in Q1 2022.
- A 5-year average of $80.9 million and a median of $90.1 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets soared 2504.44% in 2023, then retreated 3.85% in 2025.
- Over 5 years, Non-Current Assets stood at $4.9 million in 2022, then soared by 1562.31% to $81.1 million in 2023, then soared by 35.64% to $109.9 million in 2024, then gained by 7.86% to $118.6 million in 2025, then climbed by 14.2% to $135.4 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $135.4 million, $118.6 million, and $116.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 84.70 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 33.51 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 68.24 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 37.24 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 7.05 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 2.37 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 26.75 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 20.19 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 8.29 Bn |
| 10 | Perspective Therapeutics | 389.10 Mn | 389.10 Mn | - | 150.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 150.50 Mn |
| Mar 31, 2026 | 135.42 Mn |
| Dec 31, 2025 | 118.58 Mn |
| Sep 30, 2025 | 116.33 Mn |
| Jun 30, 2025 | 114.77 Mn |
| Mar 31, 2025 | 113.61 Mn |
| Dec 31, 2024 | 109.94 Mn |
| Sep 30, 2024 | 120.98 Mn |
| Jun 30, 2024 | 91.68 Mn |
| Mar 31, 2024 | 90.09 Mn |
| Dec 31, 2023 | 81.05 Mn |
| Sep 30, 2023 | 88.83 Mn |
| Jun 30, 2023 | 88.19 Mn |
| Mar 31, 2023 | 87.38 Mn |
| Dec 31, 2022 | 4.88 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.11 Mn |
| Mar 31, 2022 | 3.36 Mn |
| Dec 31, 2021 | 3.65 Mn |
| Sep 30, 2021 | 3.75 Mn |